Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

Pfizer

Status: Enrolling

Conditions: Aspergillosis; Mucormycosis

Treatments: Drug: Isauvuconazole group

Study type: Observational

Funder types: Industry

Identifiers

NCT04744454

NCT04744454 (Registry Identifier)

C3791006

Details and patient eligibility

About

The purpose of this study is to observe safety and effectiveness of Cresemba in patients with invasive Aspergillosis or invasive Mucormycosis in Korea during the post-marketing surveillance period as required by Ministry of Food and Drug Safety (MFDS).

Full description

In compliance with the Korean New Drug Re-Examination Guidelines, this study aims to collect further observational data on the safety and effectiveness of Cresemba for six years after authorization is obtained in at least 600 subjects under routine clinical practice. As the safety and effectiveness results obtained from the clinical development program of Cresemba are based on randomized trials using specific inclusion and exclusion criteria, data from the present post-authorization study where Cresemba is used in routine clinical practice per approved label is anticipated to provide important information on safety and effectiveness in a real-world population in Korea. This non-interventional study is designated as a PMS study and is a commitment to MFDS.

Enrollment: 600 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

• Patients aged 19 years or older
• Patients with proven or suspected diagnosis of invasive Aspergillosis or invasive Mucormycosis.
• Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study:

• Patients with known hypersensitivity to the active substance of Isavuconazole or to any of the excipients.
• Patients are ineligible as determined by the investigator, such as those with familial short QT syndrome.
• Patients administrating ketoconazole, high-dose ritonavir (>200 mg every 12 hours) or strong CYP3A4/5 inducers (e.g. rifampicin, carbamazepine, phenytoin) that cannot be discontinued before administration of Cresemba.